Loading...
01/10 17:25
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance, with significant sales growth across key segments and raised guidance for 2025. Despite a slight decrease in profit margins, the overall outlook remains positive, supported by new product launches and strategic investments. The Q&A section highlights management's confidence in sustained growth, although some concerns about FX impacts and litigation charges were noted. The positive physician feedback and strategic initiatives further bolster the sentiment, suggesting a positive stock price movement over the next two weeks.
Total Sales Sales in the quarter grew 12.6% to $1.55 billion year-over-year, driven by a comprehensive portfolio across multiple therapeutic areas and an established global presence.
TAVR Global Sales Third quarter global sales of $1.15 billion increased 10.6% year-over-year, driven by renewed focus on treating aortic stenosis patients, guideline updates, and expanded education.
TMTT Sales Third quarter sales of $144 million increased 53% year-over-year, fueled by strong performance of PASCAL and EVOQUE, and supported by new ESC/EACTS guidelines.
Surgical Product Sales Third quarter global sales of $258 million increased 5.6% year-over-year, driven by adoption of RESILIA therapy and positive procedure growth for patients best treated surgically.
Adjusted Gross Profit Margin Adjusted gross profit margin was 77.9%, down from 80.7% year-over-year, primarily due to foreign exchange and operational expenses.
Adjusted Operating Profit Margin Adjusted operating profit margin was 27.5%, benefiting from better-than-expected sales performance and deferred spending to Q4.
R&D Expense R&D expense was $281 million, representing 18.1% of sales, compared to 18.7% in the prior year, reflecting strategic prioritization of investments in structural heart portfolio.
SAPIEN, EVOQUE, and SAPIEN M3: Highlighted as groundbreaking transcatheter therapies with significant clinical data presented at TCT. SAPIEN platform has over 15 years of clinical trials, involving 10,000+ patients and 1.2 million treated globally. Proven durability and performance at 7 and 10 years.
PASCAL, EVOQUE, and SAPIEN M3: Differentiated portfolio for mitral and tricuspid diseases. PASCAL and EVOQUE showed strong growth, with EVOQUE demonstrating consistent tricuspid regurgitation elimination. SAPIEN M3 showed excellent outcomes in critically sick patients unsuitable for TEER and surgery.
RESILIA portfolio: Achieved double-digit growth, driven by INSPIRIS, KONECT, and MITRIS therapies. Expanded access globally, including European approval for KONECT.
TAVR (Transcatheter Aortic Valve Replacement): Global sales of $1.15 billion in Q3, up 10.6% YoY. Growth driven by new evidence, guideline updates, and expanded education. U.S. and OUS markets showed strong growth, with Europe benefiting from competitor exit and Japan showing recovery.
TMTT (Transcatheter Mitral and Tricuspid Therapies): Q3 sales of $144 million, up 53% YoY. Strong global adoption of PASCAL and EVOQUE, supported by new ESC/EACTS guidelines. Expected to grow to $2 billion by 2030.
Sales Growth: Q3 sales grew 12.6% to $1.55 billion. Full-year sales growth guidance raised to the high end of 9%-10% range. EPS guidance also raised to $2.56-$2.62.
Gross Profit Margin: Adjusted gross profit margin for Q3 was 77.9%, in line with expectations. Full-year margin expected to be 78%-79%.
R&D Investments: R&D expense was $281 million in Q3, reflecting strategic prioritization of structural heart portfolio.
Expansion into Heart Failure and Aortic Regurgitation: Leveraging structural heart expertise to extend into these areas as next-generation growth contributors.
Guideline and Policy Changes: New guidelines and policies for valvular heart disease and severe aortic stenosis are expected to drive multiyear growth opportunities.
Regulatory and Policy Changes: The company anticipates potential catalysts from new U.S. National Coverage Determination (NCD) and evolving guidelines, but these changes could also introduce uncertainties or delays in adoption.
Foreign Exchange Impact: The weakening dollar has negatively impacted gross profit margins and could continue to pose challenges to financial performance.
Supply Chain and Operational Costs: Operational expenses and foreign exchange pressures have impacted gross profit margins, and there is a risk of further cost increases.
Market Competition: While the company has a strong competitive position, the exit of a competitor in Europe has led to market rebalancing, which could introduce uncertainties in market dynamics.
Product Adoption and Market Penetration: The company is focusing on increasing therapy adoption in underpenetrated regions, but this effort may face challenges due to varying regional healthcare infrastructure and patient access.
R&D and Investment Timing: The company has deferred certain spending to Q4, which could impact the timing of strategic initiatives and operational execution.
Economic and Market Conditions: Economic uncertainties and market conditions could impact the company's ability to achieve its growth targets, particularly in regions with slower adoption rates.
Leadership Transition: The planned CFO transition by mid-2026 introduces potential risks related to leadership continuity and strategic execution.
Full Year Sales Growth Guidance: The company has raised its full year sales growth guidance to the high end of the previous 9% to 10% range.
Earnings Per Share (EPS) Guidance: EPS guidance range has been raised to between $2.56 and $2.62.
2026 and Beyond Growth Expectations: The company expects sustainable top-line growth driven by multiple growth drivers, with sales and profitability growth in line with prior commitments.
TAVR Sales Growth Guidance: Full year TAVR guidance has been raised to 7% to 8% from the previous 6% to 7% range. Long-term growth is expected to be mid- to high single digits, supported by proven long-term evidence, new indications, guideline and policy changes, and the potential to serve patients with moderate AS.
TMTT Sales Guidance: The company remains on track to achieve full year TMTT sales guidance of $530 million to $550 million. TMTT is expected to grow to an estimated $2 billion by 2030.
Surgical Sales Guidance: Full year 2025 surgical global sales are expected to grow in the mid-single digits, driven by RESILIA portfolio adoption and growth in heart valve procedures.
Fourth Quarter Guidance: Total company sales for Q4 are projected to be $1.51 billion to $1.59 billion, with adjusted EPS of $0.58 to $0.64.
Long-Term Financial Goals: The company remains confident in delivering long-term financial goals for each business unit, as outlined in the prior year's investor conference.
Dividends: The company continues to generate dividends on the RESILIA portfolio and expand access globally.
Share Repurchase Program: The Board of Directors has increased the company's repurchase authorization, resulting in approximately $2 billion remaining under the current authorization. Average diluted shares outstanding during the quarter were 586 million. Based on year-to-date share repurchases of over $800 million, including the previously announced accelerated share repurchase of $500 million, the company now expects lower full year shares outstanding to be between 585 million to 590 million versus original guidance of 585 million to 595 million.
The earnings call indicates strong financial performance, with significant sales growth across key segments and raised guidance for 2025. Despite a slight decrease in profit margins, the overall outlook remains positive, supported by new product launches and strategic investments. The Q&A section highlights management's confidence in sustained growth, although some concerns about FX impacts and litigation charges were noted. The positive physician feedback and strategic initiatives further bolster the sentiment, suggesting a positive stock price movement over the next two weeks.
The earnings call summary and Q&A reveal a positive sentiment overall. The company is confident in achieving long-term growth goals, with a focus on innovation and market expansion. Despite headwinds like the JenaValve acquisition affecting EPS guidance, the company maintains a positive outlook with strong growth expectations. The anticipated NCD updates and international expansion efforts are likely to positively impact the stock price. The company's strategy for TMTT and TAVR growth, along with the potential for increased market share, further supports a positive sentiment.
The earnings call summary presents a positive outlook with strong financial performance, particularly in TMTT sales growth. Despite some competitive and supply chain challenges, guidance remains optimistic. The Q&A reveals management's confidence in overcoming regional pressures and operational challenges. The unchanged sales growth guidance and significant share repurchase authorization further support a positive sentiment. However, the lack of clarity on regional pressures may slightly temper expectations, leading to a moderate positive outlook for the stock price.
The earnings call presents a mixed picture. Strong financial performance with a 9.6% sales increase and robust TMTT growth is offset by regulatory delays and regional pressures affecting TAVR sales. The Q&A reveals some uncertainties, particularly in Q4 guidance and management's vague responses on critical impacts. The share repurchase plan is a positive factor, but overall guidance adjustments and external challenges suggest a neutral market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
